David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.
The first patient treated in Mustang Bio‘s Phase 1/2 clinical trial testing its investigational MB-106 therapy for B-cell non-Hodgkin’s lymphoma has achieved a complete response to treatment — meaning that all signs of the ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Cellectar BioSciences‘ experimental therapy CLR 131 for lymphoplasmacytic lymphoma (LPL), or Waldenström’s macroglobulinemia, a rare type of ... Read more